The most common parts are the face, hands, feet ... Do not stop using Dupixent or any other medicines for atopic dermatitis without talking to your health care provider first, even if your ...

Regeneron and Sanofi’s blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the ...

The prescribing information for Dupixent ® (dupilumab ... “Unfortunately, treating atopic dermatitis on the hands and feet has historically been difficult and there have been no phase 3 ...

sleep and hand eczema-related quality of life. The trial demonstrated similar safety results to the known safety profile of Dupixent in atopic dermatitis. Overall rates of adverse events (AEs ...

At the American Academy of Dermatology (AAD) annual meeting, Dupixent (dupilumab) showed its worth in a clinical trial involving patients with uncontrolled atopic dermatitis of the hand and foot ...

Home page Seeking Alpha - Power to Investors Create Free Account About Premium FREE Newsletters ...

This approval marks the eighth disease indication for Dupixent as a new alternative for patients—many of whom are elderly and ...

Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler ...

Data included from first and only Phase 3 trial specifically evaluating a biologic in this difficult-to-treat populationPhase 3 trial showed more ...

At 16 weeks, patients treated with Dupixent experienced the following: 40% achieved clear or almost clear skin on hands and feet compared to 17% with placebo (p≤0.01), the primary endpoint.

one of more than 20 Dupixent scientific presentations, at the American Academy of Dermatology (AAD) 2023 Annual Meeting. “Atopic hand and foot dermatitis can extensively disrupt the lives of ...